{
  "docId": "019de073-3cb6-7521-8cc2-fe64231d84c9",
  "docSlug": "d538949ee3add2afed287b359e626655",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 25,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 9,
  "notes": "EBO = Epetraborole; MAC = Mycobacterium avium complex; MIC = Minimum Inhibitory Concentration.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/13",
  "deckHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9",
  "deckJsonHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json",
  "deckAnchorHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.68,
        "x": 0.29,
        "y": 0.75
      },
      "kind": "callout",
      "text": "EBO's novel MoA allows it to maintain activity against MAC isolates resistant to clarithromycin",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fc88af0-694a-47af-bbc0-a7104a26f5ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.68,
        "x": 0.29,
        "y": 0.38
      },
      "kind": "list",
      "text": "Antimicrobial activity of epetraborole, clarithromycin and amikacin against 51 isolates of MAC including 17 M. intracellulare isolates, 1 M. avium isolates, 3 M. avium complex isolates, 20 M. avium subsp. hominissuis isolates, and 10 M. chimaera isolates",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76e7dd56-3fbb-4b1c-b06e-3766b45c7815",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.68,
        "x": 0.29,
        "y": 0.55
      },
      "kind": "list",
      "text": "Clarithromycin is a generic macrolide antimicrobial used to treat patients with MAC lung disease and Arikayce is the only currently approved therapy for the treatment of MAC lung disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad282000-0da3-45b3-93fd-42b48dbbbc8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "EBO in vitro antimicrobial activity against 51 clinical isolates of MAC, with MICs between 0.25 µg/ml to 8 µg/ml",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edb71661-7fbc-4c61-804a-92fa377da0a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.68,
        "x": 0.29,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Unpublished Data from Michelle S. DeStefano and Michael H. Cynamon, Central New York Research Corporation Syracuse, NY, United States * Amikacin is the active component of Arikayce",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7af4d48e-f3f9-47cf-b1a6-0d37ac19aa96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.3,
        "y": 0.08
      },
      "kind": "table",
      "text": "MIC (mg/L) table comparing Epetraborole, Clarithromycin, and Amikacin across MIC Range, MIC50, and MIC90.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bd83747-f9de-4656-b788-432c8306bc3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Broad antimicrobial activity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42c982bc-5cc9-4162-af96-2c6ce94a41ff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "660fd7c9-fcd1-4f18-9657-0dbd4575d7ab",
      "evidence": "The slide presents a table comparing MIC values for Epetraborole, Clarithromycin, and Amikacin.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 12,
      "beatId": "fbdd29f4-3b4e-4837-b922-52ede9c2a8ae",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 12-14 present the solution overview, including epetraborole's novel mechanism of action and broad antimicrobial activity",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 12,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "88233dcc-135b-430e-bef3-14bb541736d0",
      "evidence": "The solution overview slides present the why, what, and how of epetraborole",
      "position": 1,
      "objective": "Why is epetraborole a compelling solution?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}